Trial Profile
Longitudinal analysis of the joint microstructure changes assesed by HR-pQCT in rheumatoid arthritis who are treated with CTLA4-Ig.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 09 Apr 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 07 Nov 2016 New trial record